A bill to amend the Public Health Service Act to streamline the...
A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.
This bill, SB5059, aims to make the approval process for biosimilar biological products quicker and more efficient. Biosimilars are complex medical treatments that are similar to existing biologic drugs but can be produced more affordably. The bill seeks to amend the Public Health Service Act to achieve this streamlining.
If passed, the bill would impact pharmaceutical companies, healthcare providers, and patients who rely on biologic treatments. The goal is to reduce the time it takes for biosimilars to be approved, which could lower costs and increase access to these essential medicines.
SB5059 was introduced on July 21, 2026, and has already been referred to the Committee on Health, Education, Labor, and Pensions for further review. The bill is in its early stages, and significant work lies ahead to determine its eventual impact.
